5-fluoro-2-((1-(4-fluorophenyl)ethyl)amino)-6-((5-methyl-1H-pyrazol-3-yl)amino)nicotinonitrile

ID: ALA5202069

PubChem CID: 56965903

Max Phase: Preclinical

Molecular Formula: C18H16F2N6

Molecular Weight: 354.36

Names and Identifiers

Canonical SMILES:  Cc1cc(Nc2nc(NC(C)c3ccc(F)cc3)c(C#N)cc2F)n[nH]1

Standard InChI:  InChI=1S/C18H16F2N6/c1-10-7-16(26-25-10)23-18-15(20)8-13(9-21)17(24-18)22-11(2)12-3-5-14(19)6-4-12/h3-8,11H,1-2H3,(H3,22,23,24,25,26)

Standard InChI Key:  SUNXHXDJOIXABJ-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 28  0  0  0  0  0  0  0  0999 V2000
    1.0721    0.7435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7867    1.1558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4986    0.7439    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4986   -0.0813    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7885   -0.4930    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0721   -0.0850    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7885   -1.3182    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2132   -0.4938    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.7867    1.9810    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7867    2.8060    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3575    1.1560    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3570    0.7435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0717    1.1560    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3570   -0.0816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7865    0.7437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4986    1.1557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4986    1.9811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7883    2.3929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0717    1.9848    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2132    2.3937    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.0739   -1.7308    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0739   -2.5559    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2697   -2.8060    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2010   -2.1525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2910   -1.4849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0262   -2.1525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  6  5  2  0
  1  6  1  0
  5  7  1  0
  4  8  1  0
  2  9  1  0
  9 10  3  0
  1 11  1  0
 11 12  1  0
 12 13  1  0
 12 14  1  0
 15 13  2  0
 16 15  1  0
 17 16  2  0
 18 17  1  0
 19 18  2  0
 13 19  1  0
 17 20  1  0
  7 21  1  0
 22 21  2  0
 22 23  1  0
 23 24  1  0
 25 24  2  0
 21 25  1  0
 24 26  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5202069

   5-fluoro-2-[1-(4-fluorophenyl)ethylamino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridine-3-carbonitrile

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 354.36

Molecular Weight (Monoisotopic): 354.1405

AlogP: 4.18

#Rotatable Bonds: 5

Polar Surface Area: 89.42

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 10.08

CX Basic pKa: 2.70

CX LogP: 4.24

CX LogD: 4.24

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.64

Np Likeness Score: -1.70

References

1. Faisal M, Kim JH, Yoo KH, Roh EJ, Hong SS, Lee SH..  (2021)  Development and Therapeutic Potential of NUAKs Inhibitors.,  64  (1.0): [PMID:33356242] [10.1021/acs.jmedchem.0c00533]

Source

Source(1):

• Scientific Literature